U.S. markets open in 9 hours
  • S&P Futures

    3,831.25
    +5.75 (+0.15%)
     
  • Dow Futures

    30,980.00
    +47.00 (+0.15%)
     
  • Nasdaq Futures

    11,694.50
    +20.25 (+0.17%)
     
  • Russell 2000 Futures

    1,741.00
    +2.70 (+0.16%)
     
  • Crude Oil

    111.23
    -0.53 (-0.47%)
     
  • Gold

    1,821.90
    +0.70 (+0.04%)
     
  • Silver

    20.76
    -0.04 (-0.20%)
     
  • EUR/USD

    1.0531
    +0.0006 (+0.05%)
     
  • 10-Yr Bond

    3.2060
    -3.1940 (-100.00%)
     
  • Vix

    28.36
    -26.95 (-100.00%)
     
  • GBP/USD

    1.2205
    +0.0020 (+0.17%)
     
  • USD/JPY

    136.2400
    +0.1120 (+0.08%)
     
  • BTC-USD

    20,261.96
    -474.74 (-2.29%)
     
  • CMC Crypto 200

    438.94
    -11.13 (-2.47%)
     
  • FTSE 100

    7,323.41
    +65.09 (+0.90%)
     
  • Nikkei 225

    26,714.57
    -334.90 (-1.24%)
     

A Ground-Breaking Clinical Trial Using Parasym(TM) Neuromodulation Device Opens Potential New Era of Treatment for Heart Failure

·5 min read

LONDON, UK / ACCESSWIRE / April 21, 2022 / Parasym™ in partnership with the University of Oklahoma announces ground-breaking research into neuromodulation treatment for heart failure.

Parasym Ltd, Thursday, April 21, 2022, Press release picture
Parasym Ltd, Thursday, April 21, 2022, Press release picture

The randomised-controlled trial, led by principal investigator Dr Stavros Stavrakis at the University of Oklahoma's Health Sciences Centre used the Parasym™ neuromodulation device to significantly improve cardiac mechanics and quality of life, and reductions in inflammatory markers in a patient population that historically has very few treatment options available. The positive results pave the way for a new era of heart failure treatment.

Currently, heart disease is the leading cause of death globally, taking an estimated 17.9 million lives each year. One person dies every 36 seconds in the United States from heart disease. In the UK heart and circulatory diseases cause a quarter of all deaths which isan average of an astounding 460 deaths per day. As the fastest growing form of heart disease, heart failure is accounting for a significant proportion of all cases.

Today's landscape for heart failure is complex as there is no cure for the debilitating condition. Until Parasym developed the first of its kind neuromodulation device, there have been no clinically validated, non-invasive, non-pharmacological options for people who suffer from heart failure and its plethora of life-altering symptoms. As many as one-quarter of patients report intermediate to severe depression in association with heart disease because it drastically impacts their quality of life. Up until now, depression as a side effect is something that the medical field has failed to focus on when considering how to treat heart failure because naturally, their priority has been the prevention of death and hospitalisation. Additionally, there are many risks and possible side effects of taking medication to treat the disease, which is mostly triggered by the right medicine ending up in the wrong places. Whereas, neuromodulation and electroceuticals can provide a highly targeted treatment.

Current treatment advises lifestyle changes and medication, which are not without side effects. Electroceuticals are set to revolutionise the treatment paradigm in heart failure, especially neuromodulation with its capacity to provide highly targeted treatment without drug interaction or side effects.

The results from the clinical trial using Parasym's neuromodulation device demonstrate that Parasym - the only non-invasive, low risk and minimal side effect option - has significantly improved the quality of life for patients suffering from heart failure. The device works by stimulating the vagus nerve and sending signals to the brain, which favourably alters the nervous system and reduces inflammation of the heart.

The clinical results of using neuromodulation to help significantly ease the symptoms of heart failure showed that the patients who took part in the placebo-controlled study experienced measurable improvements from as little as three months of using the device for less than an hour per day. The study revealed significant improvements in levels of proinflammatory cytokines Interleukin-8 and Tumour Necrosis Factor-alpha, indicating that the treatment had a significant anti-inflammatory effect, as well as in global longitudinal strain, a core indicator of cardiac mechanics.

Importantly, patients also reported improved quality of life and in their day-to-day activities, which is something that surgery and medication struggle to deliver. Furthermore, as the neuromodulation device is non-invasive, patients can use it in addition to medication should they want to. This approach fills a gap by addressing the patient's overall quality of life, as well as improving their mental health which is impacted by living with the condition.

Sophie Dundovic, Co-Founder at Parasym commented: "The international impact of heart failure on our population is staggering with millions of individuals suffering daily with symptoms impacting their quality of life. Parasym™️ is committed to supporting ground-breaking cardiac research and we are working to bring non-invasive electroceutical treatments to patients suffering from heart failure.

"The results published in the Journal of the American Heart Association highlight the brilliant work done by researchers at the University of Oklahoma and show the incredible potential that Parasym's neuromodulatory technology can have in a condition where there is an urgent unmet clinical need for new treatment options. We are incredibly proud of the trial results and hope to continue to demonstrate the positive impact of neuromodulation in healthcare."

Dr Stavros Stavrakis MD, PhD, Associate Professor at the University of Oklahoma College of Medicine commented: "In this patient population, neuromodulation with low-level transcutaneous vagus nerve stimulation over three months resulted in a significant improvement in global longitudinal strain, inflammatory cytokines, and quality of life. Our results support the emerging paradigm of non-invasive neuromodulation to treat selected patients with heart failure with preserved ejection fraction."

Parasym™ is the only company to have developed a device that utilises advances in electroceutical technology to provide ground-breaking non-invasive treatment for numerous health and wellness conditions ranging from mental to physical health including heart failure, without the need for medication. For further information about Parasym™ visit parasym.co.

About Parasym:

Founded in 2015 by Sophie and Nathan Dundovic, Parasym™ is a neurotechnology company dedicated to shaping the future of bioelectric medicine. It is focused on providing innovative neuromodulation products that restore health. The company has over 60 clinical partnerships across 4 continents, and over 1,000,000 treatment sessions completed. Parasym also helps support the environment by donating 1% of revenue to fund grassroots environmental initiatives. For more information about Parasym™'s latest products, visit nurosym.com.

Media Contact:

Email: nathan@parasym.co

Website URL: www.parasym.co

SOURCE: Parasym Ltd



View source version on accesswire.com:
https://www.accesswire.com/698311/A-Ground-Breaking-Clinical-Trial-Using-ParasymTM-Neuromodulation-Device-Opens-Potential-New-Era-of-Treatment-for-Heart-Failure